Horizon Pharma, which is launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients, raised $50 million by offering 5.5 million shares at $9, below the range of $10 to $12. Horizon Pharma plans to list on the NASDAQ under the symbol HZNP. Stifel Nicolaus Weisel, Cowen & Company, and JMP Securities acted as lead managers on the deal.
